Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Metenolone enanthate is a long-acting injectable anabolic-androgenic steroid (AAS) and a derivative of dihydrotestosterone (DHT). It is the 17β-enanthate ester of metenolone, which serves as a prodrug that allows for a slow release of the active hormone from the injection site. The drug acts as an agonist of the androgen receptor, promoting anabolic effects such as nitrogen retention and protein synthesis while exhibiting relatively low androgenic potency compared to testosterone. Historically developed by Schering, it was used clinically to treat conditions such as anemia, breast cancer, and muscle wasting syndromes associated with surgery, infection, or trauma. Although it has been discontinued in several major markets, including the United States, it remains available in some regions and is frequently used off-label for performance enhancement and bodybuilding. Sinofuture Pharma is identified as a manufacturer of the steroid API.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on metenolone enanthate.